New combo therapy offers hope for advanced bile duct cancer patients
NCT ID NCT07291063
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This study is for people with advanced bile duct cancer that cannot be removed by surgery. It tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus immunotherapy (anti-PD-1/PD-L1 antibodies) as a first treatment. The goal is to see if this combination is safe and helps shrink tumors or slow cancer growth. About 50 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Fudan university
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.